From fast-tracked clinical trials to emergency medical devices and telehealth innovations, the Life Sciences sector is providing solutions to Covid-19. This series of reports explores what risks organisations are entering into as they ride to the world’s rescue and how they can protect themselves
With the scientific community throwing everything it has at Covid-19, best practice is slipping in clinical trials. What trade-offs are being made and who is liable?
|Emerging risks in Covid-19 clinical trials|
Consumer manufacturers pivoting to help in the fight against Covid-19 have been surprised by the liabilities they face in an unfamiliar sector. But even the specialist makers of ventilators, diagnostic tests and PPE have faced challenges, some of which will linger even after the pandemic is over
|Making medical devices during a pandemic|
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
|The great telehealth experiment|
Genomics has provided us with a new armoury for tackling pandemics, enabling us to respond faster and with more accuracy to COVID-19. Behind the scenes it is also gradually redefining healthcare, ushering in a more predictive and personalised approach, with potentially big implications for drug company liability.
|Fighting COVID-19 with genomics|
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?
|Lessons from the supply chain|
Chubb provides companies in the Life Sciences sector with a simple and integrated offer that covers their specific risks in liability and property.